Clinical Trials Logo
  1. Home
  2. Diabetic Macular Edema (DME)
  3. NCT02080091

Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies — ILUMINATE  

Diabetic Macular Edema (DME) Clinical Trial

Official title:
ILUMINATE: An Open-Label, Non-Interventional Study of the Safety and Effect of Iluvien® (Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Applicator) in Patients With Chronic Diabetic Macular Edema (DME) Insufficiently Responsive to Available Therapies

Clinical Trial Summary

This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02080091
Study type Observational
Source Alimera Sciences
Contact
Status Terminated
Phase N/A
Start date December 2013
Completion date April 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT01702441 - Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema Phase 1/Phase 2
Active, not recruiting NCT04543331 - Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
Completed NCT02424019 - Phase 4 IOP Signals Associated With ILUVIEN® Phase 4
Completed NCT02633852 - Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Phase 4
Completed NCT04857996 - Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) Phase 2
Recruiting NCT05919693 - A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) Phase 1/Phase 2
Completed NCT04739306 - Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema Phase 3
Recruiting NCT06116916 - Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema Phase 2
Completed NCT02050828 - The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema Phase 2
Recruiting NCT03859245 - Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention N/A
Completed NCT02585401 - Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada N/A
Terminated NCT04697758 - Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema Phase 1/Phase 2
Terminated NCT00936520 - SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy Phase 1
Not yet recruiting NCT05989126 - Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) Phase 3